We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+28.55%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$465M
AUM Growth
+$35.8M
Cap. Flow
-$14.7M
Cap. Flow %
-3.15%
Top 10 Hldgs %
71.37%
Holding
58
New
2
Increased
2
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
PRME icon
Prime Medicine
PRME
+$8.5M
2
IMTX icon
Immatics
IMTX
+$5.12M
3
ZYME icon
Zymeworks
ZYME
+$4.57M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$4.4M

Top Sells

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$21.3M
2
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$5.05M
3
VRNA
Verona Pharma
VRNA
+$3.25M
4
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$3.01M
5
ACLX
Arcellx
ACLX
+$2.44M

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZN icon
51
Surrozen
SRZN
$301M
$175K 0.04%
20,000
– –
KRON
52
DELISTED
Kronos Bio
KRON
$127K 0.03%
78,131
– –
NGM
53
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$68.6K 0.01%
13,669
– –
NUVB.WS
54
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$19.3K ﹤0.01%
133,333
– –
SRZNW icon
55
Surrozen Inc Warrant
SRZNW
$8.86K
$5.51K ﹤0.01%
99,999
– –
JYAC
56
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
– –
-507,041
Closed -$5.05M
BLSA
57
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
– –
-300,000
Closed -$3.01M
FMTX
58
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-1,065,413
Closed -$21.3M
1 2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q4 2022 Portfolio in Review

As of Q4 2022, Samsara BioCapital held 58 positions worth $465M, up 8.3% from $429M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Samsara BioCapital withdrew a net $14.7M in Q4 2022, closing 3 positions and reducing 4 holdings. Its most notable exit was Forma Therapeutics Holdings, Inc. Common Stock, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in Prime Medicine worth $8.74M.

  • Samsara BioCapital's largest Q4 2022 buy was Prime Medicine: 470,304 shares worth $8.74M.
  • Samsara BioCapital added most to Zymeworks in Q4 2022, an estimated $4.57M increase.
  • Samsara BioCapital's biggest Q4 2022 reduction was Verona Pharma, cutting an estimated $3.25M.
  • Samsara BioCapital fully exited Forma Therapeutics Holdings, Inc. Common Stock in Q4 2022, selling an estimated $21.3M.
  • Samsara BioCapital's ten largest holdings make up 71% of its $465M portfolio in Q4 2022.
  • Samsara BioCapital opened 2 new positions and closed 3 in Q4 2022.
  • Samsara BioCapital's portfolio value rose 8.3% quarter-over-quarter to $465M.

Based on Samsara BioCapital's 13F filing for Q4 2022, filed 14 Feb 2023.